Calendar
June 18–21, 2016
July 14–15, 2016
ASH Meeting on Lymphoma Biology
ASH Workshop on Genome Editing
Colorado Springs, Colorado
The ASH Meeting on Lymphoma Biology brings together
experts from around the world to discuss the latest
breakthroughs in basic and translational lymphoma
research, address current challenges in the field, and
exchange ideas on how to move the field forward.
Washington, DC
The ASH Workshop on Genome Editing provides a forum
that focuses on the mechanistic aspects and possible
clinical applications of this technology to blood disorders
as well as a platform for the exchange of ideas between
academic researchers, industry scientists, regulators
involved in the clinical application of genome editing
technology.
Colorado Springs at night
NOW AVAILABLE...
The ASH Clinical
News iPad App!
Lyophilized Powder for Solution for Intravenous Injection
ADVERSE REACTIONS
Brief Summary of Prescribing Information: Please see
package insert for full Prescribing Information.
Common adverse reactions observed in greater than 5% of
subjects in the clinical trial were development of inhibitors to
porcine factor VIII.
INDICATIONS AND USAGE
OBIZUR, Antihemophilic Factor (Recombinant), Porcine
Sequence, is a recombinant DNA derived, antihemophilic
factor indicated for the treatment of bleeding episodes in
adults with acquired hemophilia A.
Limitations of Use:
Clinical Trials Experience
Because clinical trials are conducted under widely varying
conditions, adverse reaction (AR) rates observed in the clinical
trials of a drug cannot be directly compared to rates in the
clinical trials of another drug and may not reflect the rates
observed in clinical practice.
CONTRAINDICATIONS
The safety and efficacy of OBIZUR was evaluated in a multicenter, prospective, open-label, clinical trial that investigated
adult patients with acquired hemophilia A. Twenty-nine adult
subjects were enrolled in the study, received at least one dose
of OBIZUR and were evaluable for safety. Of the 29 adult
subjects, 10 were between the ages of 40 and 65, and 19 were
65 years of age or older (18 Caucasian, 6 African-American,
and 5 Asian). Ten (34%) subjects were female.
OBIZUR is contraindicated in patients who have had lifethreatening hypersensitivity reactions to OBIZUR or its
components (including traces of hamster proteins).
The most frequently reported adverse reaction in patients
with acquired hemophilia A was the development of inhibitors
to porcine factor VIII.
WARNINGS AND PRECAUTIONS
Immunogenicity
• Safety and efficacy of OBIZUR has not been established in
patients with baseline anti-porcine factor VIII inhibitor titer
greater than 20 BU.
• OBIZUR is not indicated for the treatment of congenital
hemophilia A or von Willebrand disease.
Hypersensitivity Reactions
Hypersensitivity reactions can occur with OBIZUR. OBIZUR
contains trace amounts of hamster proteins. Early signs of
allergic reactions, which can progress to anaphylaxis, include
angioedema, chest-tightness, dyspnea, hypotension,
wheezing, urticaria, and pruritus. Immediately discontinue
administration and initiate appropriate treatment if allergic
or anaphylactic-type reactions occur.
Inhibitory Antibodies
Inhibitory antibodies to OBIZUR have occurred. Monitor
patients for the development of antibodies to OBIZUR by
appropriate assays. If the plasma factor VIII level fails to
increase as expected, or if bleeding is not controlled after
OBIZUR administration, suspect the presence of an antiporcine factor VIII antibody. If such inhibitory antibodies
to anti-porcine factor VIII are suspected and there is a
lack of clinical response, consider other therapeutic options.
Monitoring Laboratory Tests
• Perform one-stage clotting assay to confirm that adequate
factor VIII levels have been achieved and maintained.
– Monitor factor VIII activity 30 minutes and 3 hours after
initial dose.
– Monitor factor VIII activity 30 minutes after
subsequent doses.
• Monitor the development of inhibitory antibodies to
OBIZUR. Perform a Nijmegen Bethesda inhibitor assay if
expected plasma factor VIII activity levels are not attained
or if bleeding is not controlled with the expected dose of
OBIZUR. Use Bethesda Units (BU) to report inhibitor levels.
The latest news and views
for the broader hematology/
oncology community, now
delivered to your iPad.
All subjects were monitored for development of inhibitory
antibodies to OBIZUR using the Nijmegen modification of the
Bethesda inhibitor assay. A subject was considered to have
developed an OBIZUR inhibitor if the titer was ≥0.6 Bethesda
Units (BU)/mL.
Of the 29 subjects treated with OBIZUR, 19 subjects were
negative for anti-porcine factor VIII antibodies at baseline.
Five of the 19 (26%) developed anti-porcine factor VIII
antibodies following exposure to OBIZUR. Of the 10 subjects
with detectable anti-porcine factor VIII antibodies at baseline,
2 (20%) experienced an increase in titer and eight (80%)
experienced a decr easing to a non-detectable titer.
All subjects were also monitored for development of binding
antibodies to baby hamster kidney (BHK) protein by a
validated sequential ELISA (enzyme-linked immunosorbent
assay). No patients developed de novo anti-BHK antibodies.
The detection of antibody formation is highly dependent on
the sensitivity and specificity of the assay. Additionally, the
observed incidence of antibody (including neutralizing
antibody) positivity in an assay may be influenced by several
factors, including assay methodology, sample handling,
timing of sample collection, concomitant medications, and
underlying disease. For these reasons, comparison of the
incidence of antibodies to OBIZUR with the incidence of
antibodies to other products may be misleading.
Baxalta and Obizur are trademarks of Baxalta Incorporated.
Manufactured by:
Baxalta US Inc.
Westlake Village, CA 91362 USA
U.S. License No. 140
USBS/MG114/15-0031
Download the free app
from the iTunes App Store
February 2016